The XiO enhancements include an improved Intensity Modulated Radiation Therapy (IMRT) segmentation algorithm, fluence map smoothing and DICOM dose import via Focal. Focal now provides improved tools for contouring, enabling clinicians to contour anatomy faster and more easily. Together, these new XiO and Focal features contribute to an approximate 30 percent reduction in segments and approximate 20 percent reduction in IMRT monitor units (MU)*, which translates into lower integral dose and faster treatment times.
Focal 4.62 now also features plan summation for any number of plans, allowing physicians to determine the cumulative dosimetric effects. The summed dose from multiple plans can be saved into a single plan.
In addition, the planning and contouring improvements support Elekta linear accelerators using MLCi2, which allows for multiple apertures and potentially fewer MUs to be delivered to the patient.
“Our XiO and Focal users requested these new features as ways to increase their clinical efficiency,” says Virgil Willcut, Vice President of Product Management, Physics & Research for Elekta Treatment Planning. “We listened to our customers and worked to make these new XiO and Focal releases a reality.”
*Data collected by Elekta on Smart Sequencing™ compared to step & shoot XiO plans.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.